Humira (adalimumab) is a biologic medication widely used to treat autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. It works by blocking tumor necrosis factor (TNF), a protein that drives inflammation in these diseases. For many patients, Humira has provided life-changing symptom relief.
Without insurance or manufacturer assistance, Humira remains one of the most expensive prescription drugs on the market. The high list price reflects research, development, manufacturing, and patent protections that have kept generics off the U.S. market for many years. Even with recent biosimilar competition, cash prices for most patients stay substantial.
This article explains current out-of-pocket costs for Humira without insurance coverage in 2025, factors that influence the price, available savings options, and practical steps to lower expenses. Prices can vary by pharmacy, location, and dose, so always verify with your pharmacist or provider.
What Is the List Price of Humira Without Insurance
The current list price (wholesale acquisition cost or WAC) for Humira in the United States is approximately $7,000–$7,500 per month for the standard adult dose of 40 mg every other week. A single carton containing two pre-filled 40 mg pens or syringes typically retails between $6,800 and $7,200 before any discounts.
Annual cost without insurance or assistance programs can exceed $84,000–$90,000 for a full year of treatment. This figure represents the cash price most patients would face if they paid entirely out of pocket at a retail pharmacy.
Biosimilar versions of adalimumab (introduced in 2023–2025) have begun to appear at lower list prices, but the branded Humira remains the most commonly prescribed product in many practices.
Factors That Affect the Cash Price
Pharmacy location plays a significant role. Prices in large chain pharmacies (CVS, Walgreens, Walmart) are often lower than in independent or specialty pharmacies due to negotiated contracts and higher purchase volumes.
Dose and frequency also influence cost. Patients on 40 mg weekly (common in hidradenitis suppurativa or Crohn’s disease) pay roughly double the every-other-week amount. Pediatric or lower-dose pens/syringes may have slightly different pricing.
Geographic region matters as well. Urban areas with more competition tend to offer better cash prices than rural locations. Some states have price transparency laws that require pharmacies to post current rates online.
- Main Price Influencers:
- Pharmacy chain vs independent
- Dose strength and frequency
- Geographic region
- Biosimilar vs branded product
Humira Cost Comparison Table (2025 Cash Prices)
The table below compares approximate cash prices for common Humira presentations without insurance or discounts.
| Product / Dose | Quantity per Carton | Approximate Cash Price (USD) | Typical Monthly Cost (Every Other Week) |
|---|---|---|---|
| Branded Humira 40 mg pen/syringe | 2 pens/syringes | $6,800 – $7,200 | $6,800 – $7,200 |
| Branded Humira 80 mg pen | 1 pen | $13,000 – $14,000 | $13,000 – $14,000 (weekly dosing) |
| Adalimumab biosimilar (e.g., Amjevita, Cyltezo, Yusimry) 40 mg | 2 pens/syringes | $1,000 – $3,500 | $1,000 – $3,500 |
| Adalimumab biosimilar 80 mg | 1 pen | $2,000 – $6,000 | $2,000 – $6,000 (weekly) |
Note: Biosimilar prices vary widely by pharmacy and wholesaler contracts. Some pharmacies offer biosimilars at 50–80% below branded Humira cash prices.
Biosimilars and Their Impact on Cost
Since 2023, multiple adalimumab biosimilars have launched in the U.S., including Amjevita, Cyltezo, Hadlima, Yusimry, Hyrimoz, and others. These are highly similar to Humira in safety, efficacy, and quality but are sold at substantially lower list prices.
Cash prices for biosimilars typically range from $1,000 to $3,500 per carton of two 40 mg pens/syringes, representing savings of 50–85% compared with branded Humira. Some pharmacies and discount programs offer even lower rates for uninsured patients.
Despite the lower prices, many physicians and patients continue using branded Humira due to insurance preferences, prior authorization requirements, or familiarity. Switching to a biosimilar often requires a new prescription and may involve a brief adjustment period.
Manufacturer and Patient Assistance Programs
AbbVie, the maker of Humira, offers the myAbbVie Assist program for uninsured or underinsured patients who meet income guidelines. Eligible patients can receive Humira at no cost or very low cost through this program.
Commercial insurance patients may qualify for the Humira Complete Savings Card, which reduces out-of-pocket costs to as little as $5 per month (up to a maximum benefit). The card has annual and monthly limits and requires activation through the Humira website or provider.
For biosimilars, manufacturers such as Amgen (Amjevita), Boehringer Ingelheim (Cyltezo), and Sandoz (Hyrimoz) offer similar copay cards and patient assistance programs. These can bring monthly costs down to $0–$25 for eligible commercially insured patients.
- Assistance Program Tips:
- Apply early—processing can take 2–4 weeks
- Provide income documentation if required
- Check eligibility annually as guidelines change
- Use manufacturer websites for direct enrollment
Pharmacy Discount Programs and Coupons
Third-party discount services like GoodRx, SingleCare, RxSaver, and Blink Health often provide the lowest cash prices for uninsured patients. Current GoodRx prices for branded Humira can be as low as $5,500–$6,000 per carton at participating pharmacies.
Biosimilar adalimumab products frequently appear at $1,000–$2,500 per carton through these platforms. Prices fluctuate daily and vary by ZIP code, so compare multiple services before filling.
Some pharmacies offer their own generic or store-brand discount programs that can reduce costs further. Always ask the pharmacist to run the prescription through every available discount before paying full price.
Strategies to Lower Humira Costs Without Insurance
Shop around at different pharmacies using discount card apps. Prices can differ by hundreds or thousands of dollars within the same city. Use price-comparison tools to find the best deal each month.
Consider switching to a biosimilar version of adalimumab if your doctor agrees it is appropriate. Many biosimilars are interchangeable with Humira and cost significantly less out of pocket.
Apply for patient assistance programs as soon as possible if you meet income criteria. These programs can provide free medication for qualifying uninsured or underinsured patients.
Explore state or federal programs that assist with high-cost medications. Some states have drug assistance programs for residents who fall into coverage gaps.
- Cost-Reduction Steps:
- Compare prices weekly via GoodRx or similar apps
- Ask your doctor about biosimilar options
- Apply for manufacturer patient assistance
- Check state-specific aid programs
When to Talk to Your Doctor About Cost
Discuss cost concerns openly with your rheumatologist, gastroenterologist, or dermatologist. Many providers are aware of affordability challenges and can help switch to a biosimilar, adjust dosing intervals (if clinically appropriate), or connect you with assistance programs.
If Humira is unaffordable even with discounts, ask about alternative biologics with lower cash prices or stronger patient assistance support. Several TNF inhibitors and other classes (IL-17, IL-23, JAK inhibitors) may offer comparable efficacy at different price points.
Never stop Humira abruptly without medical guidance. Sudden discontinuation can cause disease flare-ups that may require higher doses or hospital care later.
Humira remains an expensive medication without insurance, with cash prices typically ranging from $6,800 to $7,200 per month for branded product and $1,000 to $3,500 for biosimilars. Using discount cards, manufacturer assistance programs, and biosimilar alternatives can reduce costs dramatically for most uninsured patients. Talk to your doctor and pharmacist regularly to find the most affordable, effective option for your condition.
FAQ
What is the cash price of Humira without insurance in 2025?
The cash price for a carton of two 40 mg Humira pens or syringes is usually $6,800–$7,200 at most retail pharmacies. Prices can vary slightly by location and pharmacy chain. Biosimilar versions often cost $1,000–$3,500 for the same quantity.
Are Humira biosimilars much cheaper without insurance?
Yes, most adalimumab biosimilars are priced 50–85% lower than branded Humira. Cash prices commonly range from $1,000 to $3,500 per carton of two 40 mg pens/syringes, depending on the specific biosimilar and pharmacy.
Does the Humira manufacturer offer help for uninsured patients?
Yes. AbbVie’s myAbbVie Assist program provides Humira at no cost or very low cost to eligible uninsured or underinsured patients who meet income guidelines. You must apply and provide financial documentation. Approval can take 2–4 weeks.
Can GoodRx or similar cards lower Humira costs without insurance?
Yes. GoodRx and other discount platforms frequently offer branded Humira for $5,500–$6,000 per carton and biosimilars for even less. Prices change regularly, so compare multiple services and pharmacies each time you refill.
Is it safe to switch from branded Humira to a biosimilar to save money?
Yes, the FDA deems approved adalimumab biosimilars highly similar to Humira in safety, efficacy, and quality. Many are rated interchangeable, meaning they can be substituted at the pharmacy level. Discuss the switch with your prescribing doctor.
What should I do if I cannot afford Humira even with discounts?
Contact your doctor immediately. They can help apply for manufacturer assistance, switch to a biosimilar, adjust your treatment plan, or prescribe an alternative biologic with better financial support. Never stop the medication abruptly without medical guidance.